6 terminated. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Terminated 6 |
Follow Covid19: new trials by email Literature Review of Covid19 trials Research Report on Covid19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UPMC OPTIMISE-C19 Trial, a COVID-19 Study Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab - Covid19 | Phase 4 | Terminated | Erin McCreary | 4571 | 2021-03-10 | 2023-06-15 |
| Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 Apixaban 2.5 MG, Placebo - Covid19, Thrombosis | Phase 4 | Terminated | Brazilian Clinical Research Institute | 411 | 2021-03-04 | 2022-08-25 |
| COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study Dexamethasone - Covid19, Corona Virus Infection | Phase 4 | Terminated | General Practitioners Research Institute | 17 | 2021-02-16 | 2021-05-11 |
| Treatment of Nosocomial COVID-19 Anti-SARS-CoV-2 mAb - Covid19, Nosocomial Infection | Phase 4 | Terminated | University of Calgary | 46 | 2021-02-12 | 2023-04-19 |
| At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19 bamlanivimab - Covid19 | Phase 4 | Terminated | Daniel Griffin | 139 | 2021-01-04 | 2022-03-18 |
| A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults Icosapent ethyl - Covid19, Atherosclerosis | Phase 4 | Terminated | Kaiser Permanente | 39600 | 2020-08-07 | 2023-07-18 |
COVID-19 (6) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Coronavirus Infections (1) · Cross Infection (1) · Respiratory Tract Infections (1) · Thrombosis (1)
Coronaviridae Infections (6) · Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · Pneumonia (6) · Pneumonia, Viral (6) · RNA Virus Infections (6) · Respiratory Tract Diseases (6) · Virus Diseases (6) · Coronavirus Infections (5) · Respiratory Tract Infections (5) · Vascular Diseases (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1)
bamlanivimab (2) · sotrovimab (2) · Dexamethasone (1) · apixaban (1) · bebtelovimab (1) · casirivimab (1) · eicosapentaenoic acid ethyl ester (1) · etesevimab (1) · imdevimab (1)
Brazilian Clinical Research Institute (1) · Daniel Griffin (1) · Erin McCreary (1) · General Practitioners Research Institute (1) · Kaiser Permanente (1) · University of Calgary (1)
United States (3) · Brazil (1) · Canada (1) · Netherlands (1)
Alain Tremblay (1) · Dan Griffin, MD, PHD (1) · David T Huang, MD, MPH (1) · Erin McCreary, PharmD (1) · Janwillem Kocks, Prof (1) · Renato D. Lopes, MD, PhD (1) · Robert Fowler (1) · Srinivas Murthy (1)
PMID 34473343, PMID 34034784, PMID 35697146, PMID 35713300, PMID 35834252, PMID 37591523